» Articles » PMID: 31308145

Identifying New Substrates and Functions for an Old Enzyme: Calcineurin

Overview
Date 2019 Jul 17
PMID 31308145
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Biological processes are dynamically regulated by signaling networks composed of protein kinases and phosphatases. Calcineurin, or PP3, is a conserved phosphoserine/phosphothreonine-specific protein phosphatase and member of the PPP family of phosphatases. Calcineurin is unique, however, in its activation by Ca and calmodulin. This ubiquitously expressed phosphatase controls Ca-dependent processes in all human tissues, but is best known for driving the adaptive immune response by dephosphorylating the nuclear factor of the activated T-cells (NFAT) family of transcription factors. Therefore, calcineurin inhibitors, FK506 (tacrolimus), and cyclosporin A serve as immunosuppressants. We describe some of the adverse effects associated with calcineurin inhibitors that result from inhibition of calcineurin in nonimmune tissues, illustrating the many functions of this enzyme that have yet to be elucidated. In fact, calcineurin has essential roles beyond the immune system, from yeast to humans, but since its discovery more than 30 years ago, only a small number of direct calcineurin substrates have been shown (∼75 proteins). This is because of limitations in current methods for identification of phosphatase substrates. Here we discuss recent insights into mechanisms of calcineurin activation and substrate recognition that have been critical in the development of novel approaches for identifying its targets systematically. Rather than comprehensively reviewing known functions of calcineurin, we highlight new approaches to substrate identification for this critical regulator that may reveal molecular mechanisms underlying toxicities caused by calcineurin inhibitor-based immunosuppression.

Citing Articles

Exploring potential drug targets for SLE through Mendelian randomization and network pharmacology.

Xu Y, Wang Z, Jia T, Liang S PLoS One. 2025; 20(1):e0316481.

PMID: 39823480 PMC: 11741580. DOI: 10.1371/journal.pone.0316481.


Protein serine/threonine phosphatases in tumor microenvironment: a vital player and a promising therapeutic target.

Liu Y, Xia F, Zhu C, Song J, Tang B, Zhang B Theranostics. 2025; 15(3):1164-1184.

PMID: 39776803 PMC: 11700861. DOI: 10.7150/thno.104529.


Ca2+-PP2B-PSD-95 axis: A novel regulatory mechanism of the phosphorylation state of Serine 295 of PSD-95.

Chimura T, Manabe T PLoS One. 2024; 19(11):e0313441.

PMID: 39509447 PMC: 11542788. DOI: 10.1371/journal.pone.0313441.


Cyclosporine-induced alopecia:a case report, FDA adverse event reporting system analysis and literature assessment.

Wang Y, Wang Y, Xu P Front Pharmacol. 2024; 15:1453034.

PMID: 39263573 PMC: 11387167. DOI: 10.3389/fphar.2024.1453034.


Calmodulin: a highly conserved and ubiquitous Ca sensor.

Sobue K Proc Jpn Acad Ser B Phys Biol Sci. 2024; 100(7):368-386.

PMID: 39085063 PMC: 11413395. DOI: 10.2183/pjab.100.025.


References
1.
Li X, Wilmanns M, Thornton J, Kohn M . Elucidating human phosphatase-substrate networks. Sci Signal. 2013; 6(275):rs10. DOI: 10.1126/scisignal.2003203. View

2.
Hoorn E, Walsh S, McCormick J, Furstenberg A, Yang C, Roeschel T . The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011; 17(10):1304-9. PMC: 3192268. DOI: 10.1038/nm.2497. View

3.
Li S, Wang J, Ma L, Lu C, Wang J, Wu J . Cooperative autoinhibition and multi-level activation mechanisms of calcineurin. Cell Res. 2016; 26(3):336-49. PMC: 4783466. DOI: 10.1038/cr.2016.14. View

4.
Hinke S, Navedo M, Ulman A, Whiting J, Nygren P, Tian G . Anchored phosphatases modulate glucose homeostasis. EMBO J. 2012; 31(20):3991-4004. PMC: 3474922. DOI: 10.1038/emboj.2012.244. View

5.
Jin L, Harrison S . Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc Natl Acad Sci U S A. 2002; 99(21):13522-6. PMC: 129706. DOI: 10.1073/pnas.212504399. View